To determine the optimal use of liquid biopsy for diagnosing mutations in lung adenocarcinoma (LUAD), we compared the KRAS mutation status in DNA isolated from four different plasma fractions, including EVs.<h4>Methods</h4>Plasma was collected from 58 participants diagnosed with LUAD (early-stage (I, II), n = 30; late-stage (IIIB, IV), n = 28) with known KRAS mutation (KRASmt) or wild-type KRAS (KRASwt). The gene discussed is KRAS; the disease is lung adenocarcinoma.